CRNX Crinetics Pharmaceuticals Inc

Price (delayed)

$54.83

Market cap

$4.32B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.76

Enterprise value

$3.98B

Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate, ...

Highlights
CRNX's equity has surged by 62% since the previous quarter
The quick ratio has soared by 54% YoY and by 37% QoQ
CRNX's gross profit has plunged by 54% YoY and by 51% from the previous quarter
The revenue has dropped by 54% year-on-year and by 51% since the previous quarter

Key stats

What are the main financial stats of CRNX
Market
Shares outstanding
78.86M
Market cap
$4.32B
Enterprise value
$3.98B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.36
Price to sales (P/S)
2,007.91
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2,015.78
Earnings
Revenue
$1.97M
EBIT
-$235.46M
EBITDA
-$232.29M
Free cash flow
-$184.45M
Per share
EPS
-$3.76
Free cash flow per share
-$2.55
Book value per share
$12.57
Revenue per share
$0.03
TBVPS
$13.53
Balance sheet
Total assets
$978.15M
Total liabilities
$103.22M
Debt
$52.5M
Equity
$874.93M
Working capital
$865.46M
Liquidity
Debt to equity
0.06
Current ratio
17.72
Quick ratio
17.43
Net debt/EBITDA
1.48
Margins
EBITDA margin
-11,767.5%
Gross margin
100%
Net margin
-11,928.3%
Operating margin
-12,571.4%
Efficiency
Return on assets
-37%
Return on equity
-42.5%
Return on invested capital
-49.6%
Return on capital employed
-25.4%
Return on sales
-11,928.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CRNX stock price

How has the Crinetics Pharmaceuticals stock price performed over time
Intraday
2.33%
1 week
-0.27%
1 month
20.29%
1 year
193.05%
YTD
54.1%
QTD
22.42%

Financial performance

How have Crinetics Pharmaceuticals's revenue and profit performed over time
Revenue
$1.97M
Gross profit
$1.97M
Operating income
-$248.16M
Net income
-$235.46M
Gross margin
100%
Net margin
-11,928.3%
The operating margin has plunged by 196% YoY and by 127% from the previous quarter
The net margin has dropped by 192% year-on-year and by 123% since the previous quarter
CRNX's gross profit has plunged by 54% YoY and by 51% from the previous quarter
The revenue has dropped by 54% year-on-year and by 51% since the previous quarter

Growth

What is Crinetics Pharmaceuticals's growth rate over time

Valuation

What is Crinetics Pharmaceuticals stock price valuation
P/E
N/A
P/B
4.36
P/S
2,007.91
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2,015.78
The company's EPS fell by 15% YoY
CRNX's equity has surged by 62% since the previous quarter
CRNX's P/B is 28% above its 5-year quarterly average of 3.4 and 18% above its last 4 quarters average of 3.7
The P/S is 188% above the last 4 quarters average of 697.3 and 130% above the 5-year quarterly average of 873.8
The revenue has dropped by 54% year-on-year and by 51% since the previous quarter

Efficiency

How efficient is Crinetics Pharmaceuticals business performance
The company's return on sales has shrunk by 192% YoY and by 123% QoQ
The ROA has increased by 22% YoY and by 19% from the previous quarter
The company's return on equity rose by 20% QoQ and by 19% YoY
The return on invested capital rose by 14% year-on-year and by 9% since the previous quarter

Dividends

What is CRNX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CRNX.

Financial health

How did Crinetics Pharmaceuticals financials performed over time
The total assets has surged by 54% since the previous quarter
The quick ratio has soared by 54% YoY and by 37% QoQ
The debt is 94% smaller than the equity
CRNX's equity has surged by 62% since the previous quarter
CRNX's debt to equity is down by 40% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.